Kazuhiko Nakagami

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Scirrhous argyrophil cell carcinoma of the stomach with multiple production of polypeptide hormones, amine, CEA, lysozyme, and HCG

Eiichi Tahara, Hisao Ito, Kazuhiko Nakagami et al. · Cancer · 1982 · 115 citations

Tumoral Pathology, Esophageal Cancer, Gastrointestinal Oncology +13

Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

Toru Watanabe, Muneaki Sano, Shigemitsu Takashima et al. · Journal of Clinical Oncology · 2009 · 93 citations

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

Kenichi Inoue, Kazuhiko Nakagami, Mitsuhiro Mizutani et al. · Breast Cancer Research and Treatment · 2009 · 89 citations

Breast Oncology, Medicine, Phase Iii Trial +8

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study

Tomohiko Aihara, Yuichi Takatsuka, Shozo Ohsumi et al. · Breast Cancer Research and Treatment · 2010 · 49 citations

Breast Oncology, Versus Sequential Tamoxifen, Medicine +12